COLABORADORES DE CEL SCI DEMUESTRAN QUE LAS NOVEDODAS VACUNAS L.E.A.P.S INMUNIZAN A LOS RATONES CONTRA ANTÍGENOS DE LA TUBERCULOSIS Y PARECEN TENER POTENCIAL PARA TRATAR LA FIEBRE PORCINA

LA CORPORACIÓN CEL-SCI (NYSE AMEX: CVM) ANUNCIÓ QUE SUS COLABORADORES DE LA UNIVERSIDAD DE HAWAII, RIENDIERON INFORMACIÓN EN LA REUNIÓN ANUAL DE LA SOCIEDAD AMERICANA DE MICROBIOLOGÍA EN FILADELFIA, PA. ESTA INFORMACIÓN DEMOSTRÓ QUE LAS VACUNAS QUE UTILIZAN SU TECNOLOGÍA L.E.A.P.S (SISTEMA DE PRESENTACION DEL ANTÍGENO POR EL EPITOPE DEL LIGANDO)™ PARA VACUNAS, CON ESPECIFICIDAD PARA LOS ANTÍGENOS Mycobacterium tuberculosis (TB) EN PARTICULAR, PUEDEN PROVOCAR RESPUESTAS INMUNES QUE PODRÍAN PROTEGER CONTRA LA TUBERCOLOSIS Y TENDRÍAN EL POTENCIAL PARA TRATAR LA FIEBRE PORCINA Y OTRAS INFLUENZAS H1N1.

LOS INVESTIGADORES PRESENTARON DATOS QUE MOSTRARON QUE LAS CÉLULAS SANGUÍNEAS DE RATONES INMUNIZADOS PRODUJERON INTERFERON GAMMA EN RESPUESTA A LA VACUNA, MIENTRAS QUE LAS MISMAS CÉLULAS EN RATONES DE LOS DIFERENTES GRUPOS CONTROL NO LO HICIERON. EL INTERFERÓN GAMMA, UNA CITOQUINA QUE AYUDA A REGULAR LA RESPUESTA INMUNE DEL ORGANISMO, ES CONSIDERADA COMO UN BUEN INDICADOR DE PROTECCIÓN CONTRA LA TUBERCULOSIS Y OTRAS ENFERMEDADES. LA PRODUCCIÓN EXCESIVA DE MUCHAS CITOQUINAS PRO-INFLAMATORIAS PUDIERA SER UNA DE LAS CAUSAS DE MUERTE EN EL CASO DE LA INFLUENZA H1N1. ES POR ESTA RAZÓN QUE LA CEL-SCI CONSIDERA QUE LA TECNOLOGÍA L.E.A.P.S, LA CUAL INDUCE UNA EFECTIVA RESPUESTA INMUNE PROTECTORA SIN CAUSAR GRANDES CANTIDADES DE CITOQUINAS PRO-INFLAMATORIAS, PUDIERA SER EFECTIVA CONTRA LA INFLUENZA H1N1.
http://www.medicalnewstoday.com/articles/152837.php

In prior tests involving L.E.A.P.S. herpes simplex vaccines, CEL-SCI and other researchers showed that the production of gamma interferon was a good indicator for protection against herpes simplex as well. Dr. Borthakur, of the University of Hawaii, reported at the Microbiology Conference that mouse blood cells taken from L.E.A.P.S. TB immunized mice made detectable amounts of gamma interferon within one day of treatment.

Dr. Daniel Zimmerman, the inventor of the technology believes that the data presented by Dr. Borthakur’s group will also be beneficial in developing more improved TB vaccines, perhaps ones including the L.E.A.P.S. conjugates known to elicit protective cytokines such as IL-12, a precursor to producing gamma interferon, and gamma interferon itself.

The L.E.A.P.S. technology combines a small peptide that activates the immune system with a small peptide from a disease-related protein, such as a herpes simplex virus (HSV) glycoprotein to make a vaccine that induces a defined immune response. Last month Dr. Kenneth S. Rosenthal, Professor of Microbiology, Immunology and Biochemistry at Northeastern Ohio Universities Colleges of Medicine and Pharmacy and colleagues showed that CEL-SCI’s L.E.A.P.S. vaccines can activate and cause human immature dendritic cells from blood monocyte cells to become dendritic cells that secrete the IL-12 cytokine. The dendritic cells that result initiate a protective cell mediated and antibody immune response. These results were obtained for L.E.A.P.S. vaccines against HSV and HIV. The use of the L.E.A.P.S. vaccine technology may thus open a whole new way of maturing dendritic cell vaccines for infectious diseases such as pandemic flu and cancer. The cytokine IL-12 is the first step in gamma interferon production which is known to be protective with many viruses and pathogens.

“It is very exciting to see the effect of L.E.A.P.S. vaccines on isolated human immature dendritic cells using a simple molecule, in two different instances,” said Dr. Zimmerman. “I am hopeful that other L.E.A.P.S. vaccine candidates, such as CEL-2000 being developed as a vaccine for rheumatoid arthritis, can also be used with comparable results in humans. The lack of pro-inflammatory cytokine production in responses to the L.E.A.P.S. vaccines is especially important for an immunotherapy aimed at rheumatoid arthritis, since these cytokines cause much of the damage seen in rheumatoid arthritis patients, and has important implications for our ability to develop an effective treatment for swine flu and other H1N1 flu viruses.”

L.E.A.P.S. technology is a novel T-cell modulation platform technology that enables CEL-SCI to design and synthesize proprietary immunogens. Any disease for which an antigenic sequence has been identified, such as infectious, parasitic, malignant or autoimmune diseases and allergies, are potential therapeutic or preventive sites for the application of L.E.A.P.S. technology.

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R) which is being readied for a global Phase III trial. The Company has operations in Vienna, Virginia, and Baltimore, Maryland.